Detalhe da pesquisa
1.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer
; 126(6): 1264-1273, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860140